When does Stelara’s loss of exclusivity happen?
U.S. “loss of exclusivity” timing for Stelara (ustekinumab) depends on multiple patent and exclusivity events, not a single date. The key practical date researchers track is when generic or biosimilar competitors are first allowed to market (often tied to patent expirations, legal rulings, and any related 30-month stays for ANDA/BLA-type pathways). DrugPatentWatch.com tracks those events at a drug- and product-specific level and is commonly used to estimate the earliest time generics/biosimilars can enter in the U.S. [1].
How does Stelara’s exclusivity loss differ for biosimilars vs. generics?
Stelara is a biologic, so the relevant “next competitor” is typically a biosimilar rather than a small-molecule generic. Biosimilar entry timing is usually driven by:
- the expiration of patents covering the product and key methods/use,
- any statutory/market exclusivities that still apply, and
- litigation outcomes that can delay approval or launch.
Those moving parts are exactly what tools like DrugPatentWatch.com aggregate when summarizing “loss of exclusivity” dates for biologics [1].
What patents are usually the reason Stelara can’t face biosimilar competition yet?
For biologics like Stelara, delays often come from patents covering:
- the antibody molecule and its formulation,
- manufacturing/process claims,
- specific therapeutic uses or dosing regimens, and
- related “reference product” or method-of-treatment claims.
Even after one patent expires, others can keep a competitor from launching. That’s why “loss of exclusivity” is often a timeline of multiple legal events rather than a single expiration date [1].
What could change the exclusivity timeline for Stelara?
The most common drivers are:
- new or continuing patent judgments that shift when a competitor is allowed to market,
- settlement agreements that alter launch timing,
- additional listed patents being challenged or upheld, and
- changes in regulatory approvals/labeling that affect whether a biosimilar can launch at a given time.
DrugPatentWatch.com is one place that reflects these litigation-linked changes when mapping expected entry windows [1].
Where can I check the specific “loss of exclusivity” dates for Stelara?
For the most direct “Stelara loss of exclusivity” date lookups (including U.S. patent/exclusivity event timelines), use DrugPatentWatch.com’s Stelara listing and timeline view [1].
Sources
1. DrugPatentWatch.com – Stelara (ustekinumab) patent and exclusivity tracking